Laboratorio Clinico Esmeralda Inc is categorized under Medical Labs in , and active since 1974.
Laboratorio Clinico Esmeralda Inc was established in 1974, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Medical Labs business, which does work in the B2C market, and is classified as a Medical Labs, under code number 621511 by the NAICS.
If you are seeking more information, feel free to contact Nelly E Acevedo Maldonado at the company’s single location by writing to 207 Avenue Esmeralda, , 00969 or by phoning (787) 720-6943. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Laboratorio Clinico Esmeralda Inc |
| Contact Person: | Nelly E Acevedo Maldonado |
| Address: | 207 Avenue Esmeralda, , 00969 |
| Phone Number: | (787) 720-6943 |
| Website Address: | labesmeralda.com |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 1974 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Medical Labs |
| SIC Code: | 8071 |
| NAICS Code: | 621511 |
| Share This Business: |
Laboratorio Clinico Esmeralda Inc was started in 1974 to provide professional Medical Labs under the SIC code 8071 and NAICS code 621511. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Nelly E Acevedo Maldonado for inquiries that concern Laboratorio Clinico Esmeralda Inc by calling the company number (787) 720-6943, as your correspondence is most welcome. Additionally, the physical location of the single location of Laboratorio Clinico Esmeralda Inc can be found at the coordinates 18.36719,-66.110329 as well as the street address 207 Avenue Esmeralda in , 00969.
For its online presence, you may visit Laboratorio Clinico Esmeralda Inc’s website at labesmeralda.com and engage with its social media outlets through on Twitter and on Facebook.